================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
Notification of Late Filing
----------
|_| Form 10-K |_| Form 11-K |_| Form 20-F |X| Form 10-QSB |_| Form N-SAR
For Quarter Ended: June 30, 2003
Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
N/A
- --------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
- --------------------------------------------------------------------------------
NANOBAC PHARMACEUTICALS, INC.
-----------------------------
(Exact Name of Registrant as Specified in Charter)
525 West Lemon Street, Tampa, Florida, 33609
--------------------------------------------
(Address of Principal Executive Office)
================================================================================
- --------------------------------------------------------------------------------
PART II - RULES 12B-25 (B) AND (C)
- --------------------------------------------------------------------------------
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
|X| (b) The subject annual report or semi-annual report/portion thereof will
be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report/portion thereof
will be filed on or before the fifth calendar day following the
prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
- --------------------------------------------------------------------------------
PART III - NARRATIVE
- --------------------------------------------------------------------------------
State below in reasonable detail the reasons why the Form 10-KSB, 11-K, 20-F,
10-QSB or N-SAR or portion thereof could not be filed within the prescribed
time:
The Company has limited resources and due to this reason, the Company was
unable to complete this filing on a timely basis without unreasonable
effort and expense.
- --------------------------------------------------------------------------------
PART IV - OTHER INFORMATION
- --------------------------------------------------------------------------------
(1) Name and telephone number of person to contact in regard to this
notification
John D. Stanton (813) 287-9733
(2) Have all other periodic reports required (under Section 13 or 15(d) of the
Securities and Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940) during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports) been filed? If
answer no, identify report(s).
|X| YES |_| NO
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statement to be included in the subject report or portion thereof?
|X| YES |_| NO
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and; if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
A qualitative and quantitative statement cannot be provided at this time,
for reasons set forth in Part III above.
Nanobac Pharmaceuticals, Inc. has caused this notification to be signed on
its behalf by the undersigned thereunto duly authorized.
Dated: August 13, 2003 Nanobac Pharmaceuticals, Inc.
By: /s/ John D. Stanton
-----------------------
John D. Stanton
Chief Executive Officer
- --------------------------------------------------------------------------------
ATTENTION
Intentional misstatements or omissions of act constitute Federal Criminal
Violations (See 18 U.S.C. 1001).
- --------------------------------------------------------------------------------